2016

Unterarmgangrän bei "normaler" Gerinnung.
Blohm M, Lehmberg K, Schrum J, Helmke K, Ridderbusch I, Schneppenheim R, Singer D
Z GEBURTSH NEONATOL . 2016;220:133-134.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients
Groeschel S, Kühl J, Bley A, Kehrer C, Weschke B, Döring M, Böhringer J, Schrum J, Santer R, Kohlschütter A, Krägeloh-Mann I, Müller I
JAMA NEUROL. 2016;73(9):1133-40.

Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia
Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora K, Schrum J, Kremens B, Ehlert K, Albert M, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Güngör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T
HAEMATOLOGICA. 2016;101(6):741-6.

2015

A Case of a Bilateral Cicatricial Upper Eyelid Entropion After Hematopoietic Stem Cell Transplantation in Mucopolysaccharidosis Type I
Dulz S, Wagenfeld L, Richard G, Schrum J, Muschol N, Keserü M
Ophthal Plast Reconstr Surg. 2015.

Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial
Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora K, Schrum J, Kremens B, Ehlert K, Albert M, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T
J CLIN ONCOL. 2015;33(11):1265-74.

2014

Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2014;34 (4A):5-8.

2012

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens J, Hewitt A, Schrum J, Schulz A, Müller I, Stein J, Wynn R, Greil J, Sykora K, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel P, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin K, Peters C, Dini G
LANCET. 2012;379(9823):1301-1309.

2011

Severe phototoxicity associated with long-term voriconazole treatment.
Vöhringer S, Schrum J, Ott H, Höger P
J DTSCH DERMATOL GES. 2011;9(4):274-276.

2010

Proton beam therapy for loco-regional control of a recurrent mixed malignant germ cell tumor of the skull in a 22-month-old girl.
Calaminus G, Göbel U, Schrum J, Wittkugel O, Westphal M, Timmermann B
KLIN PADIATR. 2010;222(3):175-179.

Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
Friedrich C, Schrum J, Chott A, Janka-Schaub G, Kabisch H
PEDIATR BLOOD CANCER. 2010;54(4):610-612.

2009

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A
BIOL BLOOD MARROW TR. 2009;15(4):454-462.

Response to DDAVP in children with von Willebrand disease type 2.
Schneppenheim R, Budde U, Beutel K, Hassenpflug W, Hauch H, Obser T, Oyen F, Schneppenheim S, Schrum J
HAMOSTASEOLOGIE. 2009;29(2):143-148.

2008

Non-surgical management of advanced cardiac lymphoma.
Lilje C, Thiel C, Weil J, Schrum J, Stork A
J PEDIATR-US. 2008;152(3):440.

2002

Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuketang Ayuk F, Erttmann R, Kabisch H, Zander A
ANN HEMATOL. 2002;81(11):627-631.

2001

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander A
BONE MARROW TRANSPL. 2001;28(7):643-647.

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander A
BRIT J HAEMATOL. 2001;113(4):1060-1071.

1999

[Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial]
Schmitt C, David K, Hiller J, Schrum J, Bredehorst R, Vogel C, Löliger C, Erttmann R
KLIN PADIATR. 1999;211(4):314-318.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr